XNK Therapeutics to use generic name evencaleucel for lead candidate
XNK Therapeutics AB (“XNK”) today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International Nonproprietary Name (INN) for XNK’s leading drug candidate.“We are excited that the WHO now recognizes our leading drug candidate targeting multiple myeloma by recommending the generic name evencaleucel,” said Johan Liwing, CEO of XNK Therapeutics. “XNK recently announced that the first patient with multiple myeloma was treated in a Phase II clinical study